Semaglutide, liraglutide, and dulaglutide have shown reductions in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
Outside the current work, JS has received honoraria for talks and/or consultancy and/or research funding from Apitope, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Bristol-Meyers Squibb, Eli Lilly, GI Dynamics, GlaxoSmithKline, Intarcia, Ipsen, Janssen, LifeScan, MedScape, MSD, Novartis, Novo Nordisk, OmniaMed, Pfizer, Roche, Sanofi, Servier, Takeda and Ypsomed
R., Jebb, S
Wessner B, Strasser EM, Spittler A, Roth E (2003) Effect of single and combined supply of glutamine, glycine, N-acetylcysteine, and R, S-alpha-lipoic acid on glutathione content of myelomonocytic cells
Differentiated Advantage Picks : Xian Season Biotechnology Co., Ltd